Spots Global Cancer Trial Database for A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Official Title: A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Study ID: NCT01510561
Study Description
Brief Summary: 90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Banner Healthcare, Gilbert, Arizona, United States
Scottsdale Healthcare, Scottsdale, Arizona, United States
Christiana Care Health Services Helen Graham Cancer Center, Newark, Delaware, United States
Sylvester Comprehensive Cancer Center Univ. Miami, Miami, Florida, United States
Jackson North Medical Center, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Mountain States Tumor Institute, Boise, Idaho, United States
Goshen Center for Cancer Care, Goshen, Indiana, United States
Detroit Clinical Research Center, Detroit, Michigan, United States
St. Mary's Trinity Healthcare, Grand Rapids, Michigan, United States
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Weill Cornell NY Presbyterian Hospital, New York, New York, United States
Mt. Sinai Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
Ohio State University Medical Center, Columbus, Ohio, United States
Kimmel Cancer Center at Jefferson University, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Institute of Translational Oncology Research, Greenville, South Carolina, United States
Tyler Cancer Center, Tyler, Texas, United States
VA Oncology Associates, Norfolk, Virginia, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Contact Details
Name: William A Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
